Ignite Creation Date:
2025-12-18 @ 8:36 AM
Ignite Modification Date:
2025-12-18 @ 8:36 AM
Study NCT ID:
NCT06071585
Status:
None
Last Update Posted:
2023-10-06 00:00:00
First Post:
2023-09-25 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Monocentric Retrospective Observational Study for Validation of Meta-analysis of the Metatrascryptome and Transcriptome of Eosynophyl Esophagitis
Sponsor:
None
Organization:
Study Overview
Official Title:
Monocentric Retrospective Observational Study for Validation of Meta-analysis of the Metatrascryptome and Transcriptome of Eosynophyl Esophagitis (EoE TaMMA)
Status:
None
Status Verified Date:
2023-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease, primarily activated by food antigens, with the concomitant accumulation of eosinophils within the esophageal mucosal layer where the Th2-response-specific interleukin (IL) 5 and IL13 play a key role during its pathogenesis. EoE positions as an uncommon disease, with a suggested genetic basis and a 3:1 male preponderance. Its incidence rate varies between 0.1 and 1.2 cases per 10,0009 and increases annually. EoE symptoms include difficulty with eating, failure to thrive, vomiting, chest and/or abdominal pain, dysphagia, and food impaction, histologically associated with esophageal linear furrows with loss of vascularity, mucosal rings, a small-caliber lumen, strictures, mucosal exudates, and, less commonly, polyps and ulcerations. The currently adopted therapies are mainly based on proton pump inhibition, topical administration of glucocorticoids, and changes in dietary habits. However, in most patients, eosinophilic esophagitis remains a chronic disease, and if treatment is stopped, inflammation ensues and symptoms recur. This may hamper the quality of life, including vitality and general health scores, and complications may develop. Therefore, the complete comprehension of the mechanisms occurring during EoE pathogenesis remains of paramount importance to implementing and improving the therapeutic lines of intervention, ameliorating the overall patients' wellness.
A straightforward and facilitated EoE clinical diagnosis is still missing, since EoE provokes in patients symptoms overlapping with other disease manifestations, such as gastroesophageal reflux disease (GERD), eosinophilic gastrointestinal disease, and achalasia. Along with the mucosal immunity alterations, the epithelial barrier function impairment does remain a hallmark of EoE, in terms of both increased permeability and antigen sensing and EoE TaMMA .
Indeed, at the mucosal level, EoE is featured by a striking pattern of dilated interepithelial spaces, with down-regulation of proteins associated with barrier function and adhesion molecules, in turn, modulated via an IL13-dependent mechanism. As a consequence, altered epithelial permeability can lead to a permissive environment that enhances antigen presentation, which in turn leads to persistent chronic inflammation.
Despite some anatomical and molecular characterizations employed as a kind of gold standard for the definition of the EoE pathogenesis, a meta-analysis of the molecular studies may improve the understanding of the physiopathology of the disease and define molecular markers helpful for a straightforward diagnosis of EoE has not been performed yet. We recently developed and released the Inflammatory Bowel Disease (IBD) Transcriptome and Metatranscriptome Meta-Analysis web app (IBD TaMMA, https://ibd-meta-analysis.herokuapp.com/), a complete survey of all public data sets generated for IBD-related studies. TaMMA has contributed to the field of omics data meta-analysis by providing an open source framework that will enable the community to easily access, query, and 'play' with the data through a user-friendly web application and offering an unprecedented opportunity to define new hypotheses and insights for better understanding the pathogenesis of IBD.
Considering the utility that IBD TaMMA has been increasingly showing over the last months, we developed a similar meta-analysis of EoE-related public data sets visualized in an interactive web app, the EoE TaMMA, that includes studies analyzing EoE, GERD and controls (without EoE and GERD). EoE-related phenotypes were confirmed throughout the web app. To further consolidate the platform, we are proposing the validation of EoE TaMMA results in an independent cohort of EoE and GERD patients, by taking advantage of the EoE and GERD.
A straightforward and facilitated EoE clinical diagnosis is still missing, since EoE provokes in patients symptoms overlapping with other disease manifestations, such as gastroesophageal reflux disease (GERD), eosinophilic gastrointestinal disease, and achalasia. Along with the mucosal immunity alterations, the epithelial barrier function impairment does remain a hallmark of EoE, in terms of both increased permeability and antigen sensing and EoE TaMMA .
Indeed, at the mucosal level, EoE is featured by a striking pattern of dilated interepithelial spaces, with down-regulation of proteins associated with barrier function and adhesion molecules, in turn, modulated via an IL13-dependent mechanism. As a consequence, altered epithelial permeability can lead to a permissive environment that enhances antigen presentation, which in turn leads to persistent chronic inflammation.
Despite some anatomical and molecular characterizations employed as a kind of gold standard for the definition of the EoE pathogenesis, a meta-analysis of the molecular studies may improve the understanding of the physiopathology of the disease and define molecular markers helpful for a straightforward diagnosis of EoE has not been performed yet. We recently developed and released the Inflammatory Bowel Disease (IBD) Transcriptome and Metatranscriptome Meta-Analysis web app (IBD TaMMA, https://ibd-meta-analysis.herokuapp.com/), a complete survey of all public data sets generated for IBD-related studies. TaMMA has contributed to the field of omics data meta-analysis by providing an open source framework that will enable the community to easily access, query, and 'play' with the data through a user-friendly web application and offering an unprecedented opportunity to define new hypotheses and insights for better understanding the pathogenesis of IBD.
Considering the utility that IBD TaMMA has been increasingly showing over the last months, we developed a similar meta-analysis of EoE-related public data sets visualized in an interactive web app, the EoE TaMMA, that includes studies analyzing EoE, GERD and controls (without EoE and GERD). EoE-related phenotypes were confirmed throughout the web app. To further consolidate the platform, we are proposing the validation of EoE TaMMA results in an independent cohort of EoE and GERD patients, by taking advantage of the EoE and GERD.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: